If my melanoma is BRAF-positive, what are the typical targeted therapy options that would be recommended? Can you...

I'll help explain the targeted therapy options for BRAF-positive melanoma, citing current guidelines and recommendations.

According to the NCCN Guidelines for Melanoma (2023), there are two main FDA-approved targeted therapy combinations for BRAF-positive melanoma:

1. BRAF inhibitor + MEK inhibitor combinations:

• Dabrafenib + Trametinib
• Vemurafenib + Cobimetinib
• Encorafenib + Binimetinib

The National Cancer Institute (NCI) reports that these combinations typically show: Benefits:

• Rapid tumor response (often within days to weeks)
• Response rates of 65-70% in previously untreated patients
• Can help quickly control symptoms
• Can be especially helpful for patients with high tumor burden

Common side effects according to ASCO Guidelines include:

• Fever (particularly with dabrafenib + trametinib)
• Skin rash
• Joint pain
• Fatigue
• High blood pressure
• Liver function changes
• Sun sensitivity

The American Cancer Society emphasizes that before starting any targeted therapy:

• BRAF mutation testing is mandatory
• Regular heart and eye monitoring is required
• Sun protection is essential during treatment
• Regular blood tests are needed to monitor for side effects

Important notes:

1. These medications are taken orally (pills)
2. Your doctor will determine the best combination based on your specific situation
3. Regular monitoring is essential to manage side effects

Always consult with your healthcare team about which option might be best for you, as they can take into account your specific medical history and other factors.

Would you like me to explain more about any particular aspect of these treatments?